Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2024—Polymedco announced FDA 510(k) clearance of the Pathfast hs-cTnI-II, a high-sensitivity cardiac troponin assay for the diagnosis of myocardial infarction at the point of care. The test delivers results in 17 minutes on the Pathfast Biomarker analyzer using whole blood and plasma samples.
May 2024—Bosch and Randox Laboratories have entered into a strategic partnership in which the two companies will invest around €150 million in joint research, development, and distribution for new tests for Bosch’s Vivalytic platform. One goal of the partnership is to develop an in vitro diagnostic multiplex sepsis test for the Vivalytic analyzer. It will be the first test to feature Bosch’s novel BioMEMS technology.
May 2024—Stemcell Technologies announced that the FDA has granted de novo classification for its immunomagnetic plasma cell enrichment kit. The EasySep Human Bone Marrow CD138 Positive Selection kit, for in vitro diagnostic applications, is intended to enrich CD138 positive plasma cells from bone marrow samples collected from patients with multiple myeloma, as part of a preanalytical workflow. Commercial launch of the kit is planned in the European Union, Canada, the United Kingdom, and the United States.
May 2024—Pillar Biosciences announced that the FDA has approved the company’s premarket approval supplement application for its OncoReveal CDx pan-cancer solid tumor in vitro diagnostic assay. The panel covers 22 clinically relevant genes in one multiplex reaction and has a fully automatable workflow with a sample-to-report time of as little as 48 hours. Up to 46 clinical samples can be batched on a single MiSeq Dx run.
May 2024—Abbott’s i-Stat TBI cartridge has received FDA clearance for use with whole blood, allowing clinicians to help assess patients with suspected concussion at the patient’s bedside. The test measures ubiquitin C-terminal hydrolase L1 and glial fibrillary acidic protein to help evaluate patients 18 years of age and older up to 24 hours after injury. Results are available in 15 minutes on the portable i-Stat Alinity system.
May 2024—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software in Europe, the Middle East, and Africa. The software is designed to help troubleshoot quality control failures and increase confidence in patient testing results and offers on-demand access to peer reporting and quality control data. Labs new to Bio-Rad’s suite of QC data management products can get guided support and training from the company.
May 2024—Sysmex America announced it will sell hemostasis instruments and reagents to laboratories in the United States under the company’s mutual original equipment manufacturer agreement with Siemens Healthineers. The agreement allows the companies to distribute hemostasis instruments provided by Sysmex and reagents provided by Siemens under their respective brands.
May 2024—Scopio Labs announced it has been granted de novo clearance by the FDA for its Full-Field Bone Marrow Aspirate application for use on the company’s X100 and X100HT platforms. The application is designed to assist users in streamlining bone marrow aspirate review and reporting. It automates the detection and visualization of hematopoietic cells in stained smears, facilitating evaluations such as bone marrow smear quality assessment, blast cell and plasma cell estimation, and calculation of the myeloid to erythroid ratio.
May 2024—Verichem Laboratories has upgraded its Web-based, CLIA-compliant data reduction and test reporting software. The new version allows customers to save reports on the company’s server for future editing and edit previous submissions for up to three days after the initial submission. Previous submissions are autosaved so users can edit data without rekeying or reentering any other component information. The software is available to customers at no cost.
May 2024—Newcomer Supply announced it is distributing HistoCyte Laboratories cell line controls for research use only. HistoCyte uses proprietary methods to process cell lines into tissue-like controls. The products are standardized, developed, and manufactured to provide consistent morphology and staining results throughout the FFPE block. Cell line controls are available as either precut slides or in cell microarray blocks.
